Search Clinical Trials in the European Union

Duration
Visits
Efficacy phase (II)
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
501-520 of 1,738 trials

Advanced Breast and Gastric Cancers: Disitamab Vedotin with Tucatinib

We are studying a new combination of disitamab vedotin and tucatinib for patients with advanced breast and gastric cancers. The goal is to find the best dose and evaluate its safety and effectiveness.

HER2 Positive Breast CancerOesophageal AdenocarcinomaGastric Cancer1-2 yearsSafety phase (I)Efficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesOncology

Systemic Lupus Erythematosus: CABA-201 T Cell Therapy

We are studying a new T cell therapy for people with active systemic lupus erythematosus to see if it is safe and effective. This research aims to understand how it affects disease activity and overall health.

Systemic Lupus Erythematosus>2 yearsSafety phase (I)Efficacy phase (II)16-20 visitsNo PlaceboStandard MedicinesCost ReimbursementHematologyRheumatology

Hepatitis B: TherVacB Vaccine Study

We are testing a new vaccine for adults with hepatitis B to see if it is safe and how well it boosts the immune response. The study will also check if it helps reduce the virus in the body.

Chronic Hepatitis B6-12 monthsSafety phase (I)Efficacy phase (II)16-20 visitsNo PlaceboInvestigational MedicinesHepatologyInfectious Diseases

HER3-DXd for Advanced Solid Tumors

We are studying a new treatment for patients with locally advanced or metastatic solid tumors to see if it is effective and safe. This trial will help us understand how well it works and its relationship with tumor characteristics.

Locally Advanced or Metastatic Solid Tumors>2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesOncology

MB-CART19.1 for Refractory Systemic Lupus Erythematosus

We are testing a new treatment for patients with systemic lupus erythematosus that has not responded to standard therapies. The goal is to see if this new approach can provide better outcomes.

Systemic Lupus Erythematosus>2 yearsSafety phase (I)Efficacy phase (II)Rheumatology

Membranous Nephropathy: Dapagliflozin Treatment Study

We are investigating how dapagliflozin affects immune activity and kidney function in patients with Membranous Nephropathy. This study may help us understand its potential benefits for managing this condition.

Membranous Nephropathy1-2 yearsEfficacy phase (II)Confirmation phase (III)≤5 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteInternal MedicineNephrology

Inclusion Body Myositis: Ruxolitinib Treatment Study

We are investigating whether ruxolitinib can improve movement and muscle function in patients with Inclusion Body Myositis. The study also looks at safety and quality of life for participants.

Inclusion Body Myositis>2 yearsEfficacy phase (II)11-15 visitsInvestigational MedicinesCost ReimbursementPartially RemoteNeurologyRheumatology

Prostate Cancer: [225Ac]Ac-PSMA-R2 Treatment Study

We are studying a new treatment for men with advanced prostate cancer to see if it is safe and effective. This trial includes men who have been treated before and those who have not.

Advanced Prostate CancerSafety phase (I)Efficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesOncology

Axial Spondyloarthritis: Risankizumab Treatment

We are studying the effects of a new treatment for patients with very early axial spondyloarthritis. The goal is to see if it can reduce disease activity and improve overall function.

Axial Spondyloarthritis6-12 monthsEfficacy phase (II)No PlaceboStandard MedicinesInfectious DiseasesRheumatology

Frontotemporal Dementia: PBFT02 Treatment Study

We are evaluating a new treatment for adults with Frontotemporal Dementia linked to GRN or C9orf72 mutations. The study aims to understand its safety and how well it works in this specific group.

Frontotemporal DementiaSafety phase (I)Efficacy phase (II)Neurology

Opioid-Induced Bowel Dysfunction: Naldemedine Study

We are investigating how naldemedine affects bowel function in individuals using opioids like tramadol. The goal is to see if it improves gastrointestinal movement and overall bowel health.

Opioid Induced Bowel Dysfunction≤3 monthsEfficacy phase (II)6-10 visitsInvestigational MedicinesGastroenterologyInternal Medicine

Multiple Myeloma: BGB-11417 Treatment Study

We are investigating the safety and effectiveness of BGB-11417 alone and with other medications for patients with relapsed or refractory multiple myeloma. This study aims to find the best treatment options for those with a specific genetic marker.

Relapsed or Refractory Multiple Myeloma>2 yearsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesOncology

Pancreatic Cancer: Islet Cell Transplantation After Surgery

We are studying the effects of removing part or all of the pancreas and transplanting the patient's own islet cells in patients with pancreatic cancer at high risk for complications. The goal is to see if this approach improves safety and quality of life.

Pancreatic Cancer>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesGastroenterologyOncology

Lung Cancer: IPH5201 and Durvalumab Treatment Study

We are studying a combination of two treatments before and after surgery for patients with early-stage non-small cell lung cancer. The goal is to see if this approach improves tumor response and safety compared to standard treatments.

Non-Small Cell Lung Cancer (NSCLC) Stage II and III1-2 yearsEfficacy phase (II)11-15 visitsNo PlaceboInvestigational MedicinesCost ReimbursementOncology

Coronary Artery Spasm: Testing Bosentan

We are studying whether the medication bosentan can help reduce coronary artery spasms in patients with ongoing angina symptoms. The trial also aims to evaluate its effects on quality of life and safety.

Coronary Vasospasm≤3 monthsEfficacy phase (II)Confirmation phase (III)≤5 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteCardiologyInternal Medicine

iTTP Treatment: TAK-755 Study

We are testing a new treatment called TAK-755 for patients with immune-mediated thrombotic thrombocytopenic purpura. The study aims to see if it is safe and effective in reducing symptoms and preventing future episodes.

Immune-Mediated Thrombotic Thrombocytopenic Purpura (iTTP)≤3 monthsEfficacy phase (II)>20 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteHematology

Cirrhosis and Ascites: Fecal Microbiota Transfer Capsules

We are testing the safety of FMT capsules for patients with cirrhosis and ascites to see if they may help reduce immune activation. This study will also look for signs of effectiveness compared to a placebo.

Cirrhosis of the Liver1-2 yearsEfficacy phase (II)Standard MedicinesCost ReimbursementGastroenterologyHepatology

Childhood Epilepsy: Perampanel Treatment Study

We are studying the effects of perampanel, given with other epilepsy medications, in children under 18. The goal is to see if it helps reduce seizures and improve overall health and development.

Childhood EpilepsyEfficacy phase (II)Post-Trial Drug AccessNo PlaceboStandard MedicinesNeurologyPediatrics

Peripheral T-Cell Lymphoma: New Drug Combinations

We are studying whether combining Beleodaq or Folotyn with standard chemotherapy is more effective for newly diagnosed patients with Peripheral T-Cell Lymphoma. The goal is to see if these combinations improve treatment outcomes compared to standard therapy alone.

Peripheral T-Cell Lymphoma>2 yearsEfficacy phase (II)Confirmation phase (III)No PlaceboInvestigational MedicinesCost ReimbursementHematologyOncology

Linvoseltamab for Relapsed or Refractory AL Amyloidosis

We are studying whether linvoseltamab is safe and effective for adults with relapsed or refractory systemic light chain amyloidosis. The trial will help us understand its impact on blood response and overall health.

Relapsed or Refractory Systemic Light Chain Amyloidosis>2 yearsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteHematologyInternal Medicine